Home >  News >  Industry >  Pharma News >  Odisha ramps up drive...

Odisha ramps up drive against illegal sale of MTP kits

Written By :  Ruchika Sharma
Published On 2025-12-03 12:53 GMT   |   Update On 2025-12-03 12:53 GMT
Advertisement

Bhubaneshwar: In a major push to protect public health, the State Health and Family Welfare Department has intensified the state-wide drive on the illegal sale of medical termination of pregnancy (MTP) kits, misuse of abortion pills, and unsafe self-medication.

The Drugs Control Directorate has been instructed to adopt a zero-tolerance approach, with strict action against unregulated abortion-related activities, a senior Health Department official confirmed.

Advertisement
Coordinated efforts among assistant controller of drugs, drug inspectors, police, law and order authorities are being carried out at field level in all the districts. Enforcement teams are conducting raids on unauthorised sale of MTP kits, absence of pharmacists in drug stores, non-maintenance of prescription records regarding sale of MTP kits, illegal stocking, etc, as per the provisions of Drugs and Cosmetics Act and Rules.
The department has very clearly instructed to prevent such illegal acts by unscrupulous shops or agents. So far, more than 400 raids have been conducted in different districts of the State, and 234 violations have been detected.
Simultaneously, the raid/inspection reports are being examined and show-cause notices being issued. Fifty-five shop owners have been issued show-cause notice as pre-step towards prosecution. Two shops dealing with MTP kits and medicines without proper licence have been seized and steps initiated for prosecution. It has been reiterated that stringent action will continue against the distributors, wholesalers and retailers violating the statutory provisions.
Strict vigilance is also being maintained on habit-forming drugs, codeine -containing cough syrup and spurious drug rackets, added the officials.

Read also: 

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Lupin Eyes Rs 11,800 Crore Vitabiotics Buyout, Lalvani Family-Owned Brand in Focus

CDSCO Issues Risk Classification List for 187 Interventional Radiology Devices, Details

DoP Invites Fresh PLI Scheme Applications for Meropenem, Ritonavir Manufacturing

Lupin's Phase IV Report for Glycopyrronium, Vilanterol Inhalation Gets CDSCO Panel Nod

700 plus cough syrup makers under scrutiny after child deaths in MP: Anupriya Patel

ED attaches Rs 2.58 crore assets in corruption case linked to Himachal Assistant Drug Controller

JnJ Imaavy gets European Commission approval for generalised myasthenia gravis